Specific targeting of hepatitis C virus NS3 RNA helicase. Discovery of the potent and selective competitive nucleotide-mimicking inhibitor QU663

Biochemistry

Volumn 44, Issue 28, 2005, Pages 9637-9644

  Maga, Giovanni ^a,b   Gemma, Sandra ^b   Fattorusso, Caterina ^b,c   Locatelli, Giada A ^a,b   Butini, Stefania ^b   Persico, Marco ^b,c   Kukreja, Gagan ^b   Romano, Maria Pia ^b   Chiasserini, Luisa ^b   Savini, Luisa ^b   Novellino, Ettore ^b,c   Nacci, Vito ^b   Spadari, Silvio ^a,b   Campiani, Giuseppe ^b  

^a CNR   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITION; EPIDEMIOLOGY; INTERFERONS; PATIENT MONITORING; PROTEINS; RNA; SUBSTRATES;

CHRONICALLY INFECTED PATIENTS; GLOBAL EPIDEMIC; HEPATITIS C VIRUS; MOLECULAR MODELING;

VIRUSES;

ADENOSINE TRIPHOSPHATASE; NUCLEOTIDE; PEGINTERFERON; QU 633; QU 663; QUINOLINE DERIVATIVE; QUINOXALINE DERIVATIVE; QX 432; QX 449; RIBAVIRIN; RNA HELICASE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CHRONIC HEPATITIS; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; ENZYME SPECIFICITY; HEPATITIS C; HEPATITIS C VIRUS; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL;

ADENOSINE TRIPHOSPHATE; ANTIVIRAL AGENTS; BINDING SITES; BINDING, COMPETITIVE; DNA, VIRAL; ENZYME INHIBITORS; HEPACIVIRUS; HYDRAZINES; HYDROLYSIS; MOLECULAR MIMICRY; PYRAZINES; QUINOLINES; QUINOXALINES; RNA HELICASES; SUBSTRATE SPECIFICITY; VIRAL NONSTRUCTURAL PROTEINS;

HEPATITIS C VIRUS;

EID: 22244485047     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi047437u     Document Type: Article

References (10)

1. Tan, S.-L., Pause, A., Shi, Y., and Sonenberg, N. (2002) Hepatitis C therapeutics: Current status and emerging strategies, Nat. Rev. 1, 867-881.
2. Di Bisceglie, A. M., McHutchinson, J., and Rice, C. M. (2002) New therapeutic strategies for hepatitis C, Hepatology 35, 224-231.
3. Borowski, P., Schalinski, S., and Schmitz, H. (2002) Nucleotide triphosphatase/helicase of hepatitis C virus as a target for antiviral therapy, Antiviral Res. 55, 397-412.
4. Diana, G. D., and Bailey, T. R. (1997) Preparation of heterocyclic substituted carboxamides for treatment of hepatitis C, U.S. Patent 5,633,388.
5. Pollard, R. B. (1999) Analogy of human immunodeficiency virus to hepatitis C virus: The human immunodeficiency model, Am. J. Med. 107, 41S-44S.
6. Maga, G., Ramunno, A., Nacci, V., Locatelli, G. A., Spadari, S., Fiorini, I., Baldanti, F., Paolucci, S., Zavattoni, M., Bergamini, A., Galletti, B., Muck, S., Hubscher, U., Giorgi, G., Guiso, G., Caccia, S., and Campiani, G. (2001) The stereoselective targeting of a specific enzyme-substrate complex is the molecular mechanism for the synergic inhibition of HIV-1 reverse transcriptase by (R)-(-)-PPO464: A novel generation of nonnucleoside inhibitors, J. Biol. Chem. 276, 44653-44662.
7. Campiani, G., Aiello, F., Fabbrini, M., Morelli, E, Ramunno, A., Armaroli, S., Nacci, V., Garofalo, A., Greco, G., Novellino, E., Maga, G., Spadari, S., Bergamini, A., Ventura, L., Bongiovanni, B., Capozzi, M., Bolacchi, F., Marini, S., Coletta, M., Guiso, G., and Caccia, S. (2001) Quinoxalinylethylpyridylthioureas (QXPTs) as potent non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors. Further SAR studies and identification of a novel orally bioavailable hydrazine-based antiviral agent, J. Med. Chem. 44, 305-315.
8. Locatelli, G. A., Gosselin, G., Spadari, S., and Maga, G. (2001) Hepatitis C virus NS3 NTPase/helicase: Different stereoselectivity in nucleoside triphosphate utilisation suggests that NTPase and helicase activities are coupled by a nucleotide-dependent rate-limiting step, J. Mol. Biol. 313, 683-694.
9. Locatelli, G. A., Spadari, S., and Maga, G. (2002) Hepatitis C virus NS3 ATPase/helicase: An ATP switch regulates the cooperativity among the different substrate binding sites, Biochemistry 41, 10332-10342.
10. Maga, G., Hubscher, U., Pregnolato, M., Ubiali, D., Gosselin, G., and Spadari, S. (2001) Potentiation of inhibition of wild-type and mutant human immunodeficiency virus type 1 reverse transcriptases by combinations of nonnucleoside inhibitors and D- and L-(beta)-dideoxynucleoside triphosphate analogs, Antimicrob. Agents Chemother. 45, 1192-1200.